Treatment of metastatic melanoma or unresectable melanoma; immunotherapy for metastatic renal cell carcinoma; enhancement of anti-tumor immune responses by blocking CTLA-4-mediated inhibitory signaling; promotion of T cell activation, proliferation, and tumor infiltration; inhibition of regulatory T cell (Treg) immunosuppressive activity; reduction of IL-10 release; augmentation of BiAb-mediated tumor-specific cytotoxicity and cytokine production; combination therapy with nivolumab to enhance effector and memory T cell responses.